In the new issue of IAVI Report we wrote
about how researchers at the AIDS Vaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting clinical trials to test partially
effective HIV
prevention strategies, including HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combination.